Factors explaining the gender disparity in lipid-lowering treatment goal attainment rate in Chinese patients with statin therapy

[1]  D. Vågerö,et al.  Social determinants of cardiac disease biomarkers: investigating a Swedish male cohort at ages 50 and 70 , 2012, European journal of preventive cardiology.

[2]  D. Vågerö,et al.  P1-190 Social determinants of cardiac disease biomarkers: investigating a Swedish male cohort at ages 50 and 70 , 2011, Journal of Epidemiology & Community Health.

[3]  P. Amouyel,et al.  Gender differences in the implementation of cardiovascular prevention measures after an acute coronary event , 2010, Heart.

[4]  D. Waters,et al.  Low- and high-density lipoprotein cholesterol goal attainment in dyslipidemic women: The Lipid Treatment Assessment Project (L-TAP) 2. , 2009, American heart journal.

[5]  P. Amarenco,et al.  Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention , 2009, The Lancet Neurology.

[6]  P. Muennig,et al.  Socioeconomic status as an independent predictor of physiological biomarkers of cardiovascular disease: evidence from NHANES. , 2007, Preventive medicine.

[7]  Yang-feng Wu.  [The second multi-center survey of dyslipidemia management in China: goal attainment rate and related factors]. , 2007, Zhonghua xin xue guan bing za zhi.

[8]  G. Fonarow,et al.  Reduced treatment success in lipid management among women with coronary heart disease or risk equivalents: results of a national survey. , 2006, American heart journal.

[9]  Lawrence A Leiter,et al.  Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines , 2006, Current opinion in cardiology.

[10]  Fan Wu,et al.  Preventing chronic diseases in China , 2005, The Lancet.

[11]  R. Collins,et al.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.

[12]  Jiang He,et al.  Major causes of death among men and women in China. , 2005, The New England journal of medicine.

[13]  Thomas Mills,et al.  National Study of Physician Awareness and Adherence to Cardiovascular Disease Prevention Guidelines , 2005, Circulation.

[14]  K. Watson,et al.  Opportunity for Intervention to Achieve American Heart Association Guidelines for Optimal Lipid Levels in High-Risk Women in a Managed Care Setting , 2005, Circulation.

[15]  M. Pfeffer,et al.  Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. , 2004, JAMA.

[16]  K. Reynolds,et al.  Serum Total and Lipoprotein Cholesterol Levels and Awareness, Treatment, and Control of Hypercholesterolemia in China , 2004, Circulation.

[17]  Neil J Stone,et al.  Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines , 2004, Circulation.

[18]  Arleen F. Brown,et al.  Income‐Related Differences in the Use of Evidence‐Based Therapies in Older Persons with Diabetes Mellitus in For‐Profit Managed Care , 2003, Journal of the American Geriatrics Society.

[19]  D. Corella,et al.  Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner. , 2001, Atherosclerosis.

[20]  M. Savolainen,et al.  Mechanisms regulating LDL metabolism in subjects on peroral and transdermal estrogen replacement therapy. , 2000, Arteriosclerosis, Thrombosis and Vascular Biology.

[21]  T. Pearson,et al.  The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. , 2000, Archives of internal medicine.

[22]  L. Speroff,et al.  The heart and estrogen/progestin replacement study (HERS). , 1998, Maturitas.

[23]  J. Avorn,et al.  Persistence of use of lipid-lowering medications: a cross-national study. , 1998, JAMA.

[24]  D. Hunninghake,et al.  Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study) , 1998, The American journal of cardiology.

[25]  Bittner,et al.  Adherence to National Cholesterol Education Program Treatment goals in postmenopausal women with heart disease. The Heart and Estrogen/Progestin Replacement Study (HERS). The HERS Research Group. , 1997, JAMA.

[26]  David M. Herrington,et al.  Adherence to National Cholesterol Education Program Treatment Goals in Postmenopausal Women With Heart Disease: The Heart and Estrogen/Progestin Replacement Study (HERS) , 1997 .

[27]  P. Clifton,et al.  A comparative study of the efficacy of simvastatin and gemfibrozil in combined hyperlipoproteinemia: prediction of response by baseline lipids, apo E genotype, lipoprotein(a) and insulin. , 1997, Atherosclerosis.

[28]  Scandinavian Simvastatin Survival Study Group.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.

[29]  J. Slattery,et al.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.

[30]  S. Grundy,et al.  Hypercholesterolemia in postmenopausal women: Metabolic defects and response to low‐dose lovastatin , 1994, JAMA.

[31]  J. Davignon,et al.  The response to lovastatin treatment in patients with heterozygous familial hypercholesterolemia is modulated by apolipoprotein E polymorphism. , 1993, Metabolism: clinical and experimental.

[32]  C. Ehnholm,et al.  Effect of apolipoprotein E polymorphism and Xbal polymorphism of apolipoprotein B on response to lovastatin treatment in familial and non‐familial hypercholesterolaemia , 1991, Journal of internal medicine.

[33]  P. de Knijff,et al.  Influence of apo E polymorphism on the response to simvastatin treatment in patients with heterozygous familial hypercholesterolemia. , 1990, Atherosclerosis.

[34]  M. Kennedy,et al.  Clinical Implications of Pharmacogenetic Variation on the Effects of Statins , 2011, Drug safety.

[35]  Liancheng Zhao,et al.  Current status of cholesterol goal attainment after statin therapy among patients with hypercholesterolemia in Asian countries and region: the Return on Expenditure Achieved for Lipid Therapy in Asia (REALITY-Asia) study. , 2008, Current medical research and opinion.

[36]  [Chinese guidelines on prevention and treatment of dyslipidemia in adults]. , 2007, Zhonghua xin xue guan bing za zhi.